GE HealthCare Technologies Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 1,245 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• GE Aerospace does not currently hold any GE HealthCare shares. GEHC's DEF 14A filed 2026-03-19 (period/measurement date 2026-03-09) states directly, in the director-independence discussion of H. Lawrence Culp Jr. (Chairman and CEO of GE Aerospace and non-executive Chairman of GEHC's board): 'Given the time since the Spin-Off and that GE does not hold any shares of our common stock, the Board determined that such affiliation does not interfere with his exercise of independent judgment.' Consistent with this, the same proxy's 5% Beneficial Owners table (as of 2026-03-09) lists only The Vanguard Group, BlackRock Inc., Dodge & Cox, and Capital Research Global Investors, no GE/GE Aerospace entity. GE Aerospace's own Q2 2026 10-Q (CIK 0000040545, filed 2026-07-16, period 2026-06-30) mentions GE HealthCare only in tax-matters-agreement and separation-cost context, with no reference to a retained equity stake. Source: https://www.sec.gov/Archives/edgar/data/1932393/000193239326000021/gehc-20260318.htm and https://www.sec.gov/Archives/edgar/data/40545/000004054526000049/ge-20260630.htm
• Holdings is intentionally empty. Searched GEHC's FY2025 10-K (filed 2026-02-04) and Q2 2026 10-Q (filed 2026-07-29) for equity-method and venture-style investments using the terms: 'equity method', 'joint venture', 'unconsolidated', 'non-marketable', 'nonmarketable', 'China joint', '% interest in', '% equity interest', 'we own approximately', 'Our share of the results'. Both filings disclose only a COMBINED 'Equity method and other investments' balance ($362 million as of 2026-06-30; $351 million as of 2025-12-31) and a combined 'Equity investments without readily determinable fair value' balance ($217 million as of 2025-12-31), with no investee named or broken out individually. The only named equity-method investee found anywhere in these filings, Nihon Medi-Physics Co., Ltd. (NMP), a former 50/50 joint venture with Sumitomo Chemical in Japanese radiopharmaceuticals, was fully acquired for the remaining 50% (net cash consideration $271 million) on 2025-03-31 and is now a wholly owned, consolidated subsidiary, excluded per the brief's wholly-owned-subsidiary rule. No China joint venture or any other named JV/unconsolidated entity was found. No single-investee balance exists to attach to any target, so per the brief's rule against assigning a combined balance to one investee, no holdings rows were created.
• Capital Group family: all three registrants (Capital Research Global Investors CIK 0001422848, Capital World Investors CIK 0001422849, Capital International Investors CIK 0001562230) were checked for Q2 2026 (period 2026-06-30) using both name search and a raw grep of cusip 36266G107 against each filer's information table XML. Capital World Investors and Capital International Investors have zero rows for this cusip in their Q2 2026 13F-HR filings. Capital Research Global Investors has one: 394,148 shares, $25,229,418, issuer name as filed 'GE HEALTHCARE TECHNOLOGIES I'; this filing's cover page confirms it is complete (tableEntryTotal 426 matches 426 parsed rows, isConfidentialOmitted false). This is a real, filing-confirmed reduction, not a search-term miss: the SAME entity's own Q1 2026 13F-HR (period 2026-03-31, CIK 0001422848 accession 0001422848-26-000041, independently read in this pass) shows 21,108,753 shares of the same cusip, so the family cut roughly 20.7 million shares (about 98%) in the quarter between 2026-03-31 and 2026-06-30. That Q1 figure in turn is consistent in direction with the proxy's older citation of a Schedule 13G showing 24,972,556 shares (5.5%) as of an even earlier date (13G filed 2025-11-13). Reading the two figures together, the position appears to have been large and roughly stable through late 2025 and Q1 2026, then sold down sharply in Q2 2026. The register row uses the directly read, most current Q2 2026 13F figure (394,148 shares) as required by the brief; the Q1 2026 figure is reported here only as corroboration that the Q2 reading is a genuine change in the position, not a data-collection error, and is not itself used anywhere in the file's numbers.
• Register self-gate as computed by the brief's script: 10 rows; raw shares sum with the director/officer aggregate reduced to its residual (1,631,245 minus Arduini's 510,320 = 1,120,925) and every other row (including Arduini) at full value = 165,416,436 shares against 451,686,252 shares outstanding = 36.62% of the company. Within the expected 25-45% band.